Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice

被引:0
|
作者
Martinez, X
Li, XM
Kovarik, J
Klein, M
Lambert, PH
Siegrist, CA
机构
[1] Univ Geneva, Sch Med, Dept Pathol, WHO Collaborating Ctr Neonatal Vaccinol, CH-1211 Geneva, Switzerland
[2] Univ Geneva, Sch Med, Dept Pediat, CH-1211 Geneva, Switzerland
[3] Pasteur Merieux Connaught Canada, Res Ctr, N York, ON, Canada
关键词
respiratory syncytial virus; DNA vaccine; neonate; infant; maternal antibody;
D O I
10.1002/(SICI)1521-4141(199910)29:10<3390::AID-IMMU3390>3.0.CO;2-A
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early life responses to respiratory syncytial virus (RSV)-F DNA and RSV-F protein immunization were studied in murine models of neonatal immunization. RSV-F DNA induced similar antibody (Ab) responses, antigen-specific IFN-gamma production and cytotoxic T lymphocyte (CTL) responses in 1-week-old and adult BALB/c mice. In contrast, RSV-F protein induced much higher IL-5 responses in early life. Both vaccines elicited Ab and CTL responses in spite of maternal Ab, but with distinctive kinetics. Sequential RSV-F DNA priming/protein boosting primed 1-week-old mice for RSV-F-specific CTL responses, reduced IL-5 production and enhanced Ab responses. In contrast, IL-5 exceeded IFN-gamma responses when young mice were primed with protein and boosted with DNA. Last, when protein and DNA immunization were combined, a single vaccine dose induced early Ab responses, preferential IL-5 responses but strong CTL responses. Sequential or combined DNA/protein immunization thus represent interesting strategies for early life immunization.
引用
收藏
页码:3390 / 3400
页数:11
相关论文
共 50 条
  • [21] Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood
    Scotta, Marcelo Comerlato
    Stein, Renato Tetelbom
    JORNAL DE PEDIATRIA, 2023, 99 : S4 - S11
  • [22] Current concepts on active immunization against respiratory syncytial virus for infants and young children
    Kneyber, MCJ
    Kimpen, JLL
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (07) : 685 - 696
  • [23] Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
    Rossey, Iebe
    Saelens, Xavier
    EXPERT REVIEW OF VACCINES, 2019, 18 (10) : 1053 - 1067
  • [24] Respiratory syncytial virus infection and the need for immunization in Korea
    Kim, Hye Young
    Yun, Ki Wook
    Cheong, Hee Jin
    Choi, Eun Hwa
    Lee, Hoan Jong
    EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 327 - 340
  • [25] The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3
    Josey E.A.
    International Journal of Pharmaceutical Medicine, 2001, 15 (4) : 175 - 190
  • [26] Vaccines for Respiratory Syncytial Virus Prevention in Older Adults
    Wroblewski, Daniel
    Brust-Sisti, Lindsay A.
    Bridgeman, Matthew
    Bridgeman, Mary Barna
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (12) : 1218 - 1228
  • [27] Development of respiratory syncytial virus (RSV) vaccines for infants
    Gerretsen, Hannah E.
    Sande, Charles J.
    JOURNAL OF INFECTION, 2017, 74 : S143 - S146
  • [28] Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus
    Abbasi, Haleema Q.
    Oduoye, Malik O.
    HEALTH SCIENCE REPORTS, 2023, 6 (10)
  • [29] Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein
    Rollier, C
    Charollois, C
    Jamard, C
    Trepo, C
    Cova, L
    VACCINE, 2000, 18 (27) : 3091 - 3096
  • [30] The pharmacist, a key player in the fight against the respiratory syncytial virus
    Nexon, Marion
    ACTUALITES PHARMACEUTIQUES, 2024, 63 (639): : 35 - 39